Revisiting 'Hallmarks of Cancer' In Sarcomas.

cancer biology hallmarks of cancer precision medicine sarcoma

Journal

Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920

Informations de publication

Date de publication:
2024
Historique:
received: 02 12 2023
accepted: 08 01 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

There is no doubt that anyone who has participated in cancer care or research has once read the 'Hallmarks of Cancer' papers published by Hanahan and Weinberg in 2001 and 2011. They initially defined the six qualities of cancer cells as cancer hallmarks in 2001, but expanded that to 11 as a next generation in 2011. In their papers, they discussed the potential treatment strategies against cancer corresponding to each of the 11 hallmarks, and to date, proposed therapies that target genes and signaling pathways associated with each of these hallmarks have guided a trail that cancer treatments should take, some of which are now used as standard in clinical practice and some of which have yet to progress that far. Along with the recent advances in cancer research such as genomic analysis with next generation sequencing, they can be reconverged to an alternative six categories defined as selective proliferative advantages, altered stress response, deregulated cellular metabolism, immune modulation and inflammation, tumor microenvironment, tissue invasion and metastasis. In this paper, we will overview the current state of these alternative hallmarks and their corresponding treatments in the current sarcoma practice, then discuss the future direction of sarcoma treatment.

Identifiants

pubmed: 38434982
doi: 10.7150/jca.92844
pii: jcav15p1786
pmc: PMC10905407
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1786-1804

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Auteurs

Kanya Honoki (K)

Dept. Of Orthopedic Oncology & Reconstructive Medicine, Nara Medical University, Japan.

Toshifumi Tsujiuchi (T)

Dept. of Life Sciences, Kindai University, Japan.

Shingo Kishi (S)

Dept. of Clinical Pathology, Nozaki Tokushukai Hospital, Japan.

Hiroki Kuniyasu (H)

Dept. of Molecular Pathology, Nara Medical University, Japan.

Classifications MeSH